Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Urinary Incontinence
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Urinary Incontinence
    Visceral Peritoneal Closure Associated With More Incontinence Immediately After Caesarean Section Than Non-Closure: Presented at ASRM - (DGDispatch)
    Solifenacin Improves Symptoms in Children With Overactive Bladder: Presented at AAP - (DGDispatch)
    TopAbstracts in Urinary Incontinence 10/20/2009 - (DGNews)
    No New Adverse Events Observed With Use of Duloxetine for Urinary Incontinence in Real World Setting: Presented at ICS - (DGDispatch)
    Tolterodine Increases Heart Rate Compared With Darifenacin, Placebo in Patients With Overactive Bladder: Presented at ICS - (DGDispatch)

    News archive

     Recent webcasts/CME - Urinary Incontinence
    • Managing Insomnia in Older Women: A Case-Based Approach
    • Evaluation and Management of a 53-Year-Old Woman Presenting With Disturbed Sleep
    • Insomnia Treatment Considerations in a 65-Year-Old Woman With Urinary Urgency
    • Frequently Asked Questions in the Evaluation and Management of Overactive Bladder
      Urinary Incontinence: Addressing and Treating a Common Yet Embarrassing Condition for Your Patient

      Webcasts/CME archive

       Recent cases - Urinary Incontinence
        Overactive Bladder in the Geriatric Patient
        A Simple Way to Achieve Temporary Continence in the Mitrofanoff Conduit

        Cases archive
          




        my personal edition > urinary incontinence > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Botulinum Toxin Improves Urinary Continence in Multiple Sclerosis Patients with Overactive Bladder: Presented at AUA

        By Ed Susman
        Special to DG News

        ORLANDO, FL -- May 28, 2002 -- Botulinum toxin injection appears to return bladder control to patients with urinary incontinence secondary to multiple sclerosis, according to researchers.

        "Botulinum toxin injections are an effective and promising treatment for patients with incontinence due to problems in controlling their bladder," said Michael Chancellor, MD, professor of urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. He presented the results of two studies here Monday at the 97th annual meeting of the American Urological Association (AUA).

        Dr. Chancellor described his use of botulinum toxin-commonly known as Botox-in 25 patients with multiple sclerosis and 50 patients with overactive bladder. He said patients with multiple sclerosis frequently suffer urinary problems because nerve damage caused by the disease prevents signals from reaching the external sphincter muscle. Injection of botulinum relaxed the external sphincter, and the internal sphincter at the neck of the bladder prevented unwanted leakage of urine.

        For patients with overactive bladder, Dr. Chancellor located the bladder through a fiber optic scope and injected the bladder with 100 to 300 units of botulinum toxin, which calmed the bladder spasms.

        "People with these conditions have to wear diapers[or] are fitted with catheters and urine bags," he said. "Some of these people are almost hopeless."

        Dr. Chancellor said about two-thirds of the study patients experienced enough relief to discard their catheters and diapers, and many were able to discontinue medicine used to control overactive bladder.

        The injections are effective for about six months, but the treatments are not curative and must be repeated.

        "I haven't seen any unwanted side effects with the treatment," he said.

        "The use of botulinum for treating overactive bladder sounds reasonable," said Thomas Brady, MD, head of the AUA's media committee and a faculty member at the University of Nevada, Reno. "The treatment is quite feasible as well. We can get needles into the bladder to make all kinds of injections, so this would not require any greater amount of expertise that doctors already have."

        Dr. Chancellor said the downside of the treatment is its cost. A vial of botulinum toxin costs about $400 for 100 units of the drug. A single bladder procedure can use one to three vials. And while the treatment may be the only thing that works for these patients, insurance companies often will not pay for the injections because botulinum toxin does not have FDA approval for this indication.

        Dr. Chancellor said he has urged the manufacturers of botulinum toxin to fund a study to prove its worth as a treatment for incontinence, but so far the companies have not responded favorably.

        The studies were institutionally sponsored.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send